methoxyhydroxyphenylglycol has been researched along with Disease Exacerbation in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Jacobs, HIL; Riphagen, JM; van Egroo, M | 1 |
Aerts, T; Coppus, AM; De Deyn, PP; Dekker, AD; Kremer, BP; Naudé, PJ; Van Dam, D; van Duijn, CM; Vermeiren, Y | 1 |
Evangelopoulos, ME; Karahalios, G; Koutsis, G; Mandellos, D; Markianos, M; Sfagos, C | 1 |
Fujimiya, T; Hakucho, A; Liu, J; Okamura, N; Takase, I | 1 |
Izumi, T; Masuda, T; Matsunaga, A; Matsuyama, N; Obuchi, S; Sato, K; Shiba, Y; Shimizu, S; Shimohama, T; Yamamoto, S | 1 |
5 other study(ies) available for methoxyhydroxyphenylglycol and Disease Exacerbation
Article | Year |
---|---|
Elevated Norepinephrine Metabolism Gauges Alzheimer's Disease-Related Pathology and Memory Decline.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Cohort Studies; Disease Progression; Female; Humans; Learning; Locus Coeruleus; Male; Memory Disorders; Methoxyhydroxyphenylglycol; Middle Aged; Neuropsychological Tests; Norepinephrine; Predictive Value of Tests; tau Proteins | 2021 |
Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Disease Progression; Dopamine; Down Syndrome; Female; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephrine; Peptide Fragments | 2015 |
Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
Topics: Adolescent; Adult; Disability Evaluation; Disease Progression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Middle Aged; Multiple Sclerosis; Neurotransmitter Agents; Regression Analysis; Severity of Illness Index; Young Adult | 2009 |
Carvedilol attenuates the progression of alcohol fatty liver disease in rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Vessels; Blotting, Western; Carbazoles; Carvedilol; Central Nervous System Depressants; Disease Progression; Ethanol; Fatty Liver, Alcoholic; Fluorescent Antibody Technique; Hepatic Stellate Cells; Immunohistochemistry; Liver; Liver Cirrhosis; Male; Methoxyhydroxyphenylglycol; Propanolamines; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Sympathetic Nervous System; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model.
Topics: Animals; Basilar Artery; Biomarkers; Brain; Cerebral Angiography; Creatine Kinase; Creatine Kinase, MB Form; Disease Models, Animal; Disease Progression; Dogs; Electrocardiography; Epinephrine; Heart Diseases; Hemodynamics; Isoenzymes; Methoxyhydroxyphenylglycol; Norepinephrine; Subarachnoid Hemorrhage; Sympathetic Nervous System; Troponin T; Ventricular Function, Left | 2002 |